Gilead Sciences, Inc. Harvoni Takes Off, Says Leerink Partner

March 27, 2015 6:25 PM

5 0

Leerink Partner talks about Gilead’s Harvoni drug weak-over-weak data disclosed by IMS, citing the launch is now trending ahead of Sovaldi

Leerink Partner, an investment bank, has discussed the IMS data following the launch of Gilead Science’s Harvoni, which is currently trending ahead of Sovaldi.

Also read: Cameron Wake's new two-year deal worth $19 million, per source

Read more

To category page